Biotechnology · Boston, Massachusetts, United States
$2.32
+0.87% (+$0.02)2026-07-10
Smart-Money SignalNeutral · 53/100— Insiders are net buyers over 90 days ($151K, 4 buys vs 0 sales)
Revenue$0
Net Income-$18.3M
Market Cap$417.8M
Price Performance
Historical data including institutional events
Company Profile
T
Thomas Schuetz
CEO & Executive Director
Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, develops antibody-based therapeutics for the treatment of various human diseases in the United States.
The companyâs lead product candidate, tovecimig, is a bispecific antibody that targets delta-like ligand 4 (DLL4) and vascular endothelial growth factor A (VEGF-A), which are critical to angiogenesis and tumor vascularization.
It also develops CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells; CTX-8371, a bispecific inhibitor that targets programmed cell death protein-1 (PD-1) and ligand PD-L1 checkpoint inhibitor antibodies; and CTX-10726, a bispecific antibody that targets PD-1 and VEFG-A.
The company was founded in 2014 and is headquartered in Boston, Massachusetts.
